Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18899114 | 1.00 | ATM (0.30) | ATML3MBTL1 | |
| SCHEMBL24541 | 0.98 | — | — | |
| SCHEMBL18372673 | 0.95 | ATM (0.30) | ATML3MBTL1 | |
| SCHEMBL26050137 | 0.95 | ATM (0.30) | ATML3MBTL1 | |
| SCHEMBL26052834 | 0.95 | ATM (0.30) | ATML3MBTL1 | |
| SCHEMBL24571795 | 0.91 | — | — | |
| SCHEMBL21185111 | 0.91 | — | — | |
| SCHEMBL18576891 | 0.87 | CYP1A2 (0.35) | ATML3MBTL1 | |
| SCHEMBL18576605 | 0.87 | CYP1A2 (0.35) | ATML3MBTL1 | |
| SCHEMBL18573248 | 0.87 | CYP1A2 (0.35) | ATML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023192375-A1 | HSD17B13 INHIBITORS AND USES THEREOF | FL2022-001, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| EP-4122927-A1 | SUBSTITUTED PYRIMIDINE OR PYRIDINE AMINE DERIVATIVE, COMPOSITION THEREOF, AND MEDICAL USE THEREOF | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. (CN) | 2023-01-25 | — | — | EP | disclosed |
| WO-2021043209-A1 | RET INHIBITOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 广东东阳光药业有限公司 | 2021-03-11 | — | — | WO | disclosed |
| WO-2020147848-A1 | TRICYCLIC SUBSTITUTED OXASPIRO DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | 上海海雁医药科技有限公司 | 2020-07-23 | — | — | WO | disclosed |
| US-9845443-B2 | Synthesis of a novel odorant | VAZE KEDAR RAMESH (IN) | 2017-12-19 | — | — | US | disclosed |
| US-9845443-B2 | Synthesis of a novel odorant | VAZE KEDAR RAMESH (IN) | 2017-12-19 | — | — | US | disclosed |
| US-9845443-B2 | Synthesis of a novel odorant | VAZE KEDAR RAMESH (IN) | 2017-12-19 | — | — | US | disclosed |
| US-20170355695-A1 | SMYD Inhibitors | Epizyme, Inc. (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170190676-A1 | Isoxazole Carboxamide Compounds | Epizyme, Inc. (US) | 2017-07-06 | — | — | US | disclosed |
| EP-2609184-B1 | PERFUMERY COMPOSITIONS AND SYNTHESIS OF A ODORANT | VAZE KEDAR RAMESH (IN) | 2017-02-15 | — | — | EP | disclosed |
| US-20160024424-A1 | SYNTHESIS OF A NOVEL ODORANT | VAZE KEDAR RAMESH (IN) | 2016-01-28 | — | — | US | disclosed |
| US-20160024424-A1 | SYNTHESIS OF A NOVEL ODORANT | VAZE KEDAR RAMESH (IN) | 2016-01-28 | — | — | US | disclosed |
| US-9187709-B2 | Synthesis of a novel odorant | VAZE KEDAR RAMESH (IN) | 2015-11-17 | — | — | US | disclosed |
| US-9187709-B2 | Synthesis of a novel odorant | VAZE KEDAR RAMESH (IN) | 2015-11-17 | — | — | US | disclosed |
| US-9187709-B2 | Synthesis of a novel odorant | VAZE KEDAR RAMESH (IN) | 2015-11-17 | — | — | US | disclosed |
| EP-2609184-A1 | SYNTHESIS OF A NOVEL ODORANT | Vaze, Kedar Ramesh (IN) | 2013-07-03 | — | — | EP | disclosed |
| US-20130157923-A1 | SYNTHESIS OF A NOVEL ODORANT | VAZE KEDAR RAMESH (IN) | 2013-06-20 | — | — | US | disclosed |
| US-20130157923-A1 | SYNTHESIS OF A NOVEL ODORANT | VAZE KEDAR RAMESH (IN) | 2013-06-20 | — | — | US | disclosed |
| US-20130157923-A1 | SYNTHESIS OF A NOVEL ODORANT | VAZE KEDAR RAMESH (IN) | 2013-06-20 | — | — | US | disclosed |
| WO-2012025934-A1 | SYNTHESIS OF A NOVEL ODORANT | VAZE KEDAR RAMESH (IN) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190676-A1 | Isoxazole Carboxamide Compounds | SMYD3, SMYD2, SNRPD3 | ATM 1643/4885L3MBTL1 1205/4885 |
| US-20170355695-A1 | SMYD Inhibitors | SMYD3, SMYD2, SMURF2 | ATM 2613/4885L3MBTL1 660/4885 |
| US-20160024424-A1 | SYNTHESIS OF A NOVEL ODORANT | OR10J3, OR51E2, TAS2R10 | ATM 3024/4885L3MBTL1 421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.